Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | OBI-902 |
| Synonyms | |
| Therapy Description |
OBI-902 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TACSTD2 (TROP2) linked to a topoisomerase I inhibitor, which may inhibit tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4356). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| OBI-902 | OBI 902|OBI902 | TROP2 Antibody 18 | OBI-902 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TACSTD2 (TROP2) linked to a topoisomerase I inhibitor, which may inhibit tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4356). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07124117 | Phase Ib/II | OBI-902 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |